Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DASETTA 1/35 vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of an estrogen (ethinyl estradiol) and a progestin (norethindrone). Suppresses gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, induces changes in cervical mucus (impenetrability to sperm) and endometrium (reduced likelihood of implantation).
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet orally once daily, each containing 1 mg norethindrone acetate and 35 mcg ethinyl estradiol.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Norethindrone: 5-14 hours (mean 8 hours); ethinyl estradiol: 10-20 hours (mean 14 hours). Clinical context: steady-state achieved within 5-7 days.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Ethinyl estradiol is metabolized primarily by CYP3A4, with sulfation and glucuronidation also involved. Norethindrone is metabolized via reduction and conjugation (sulfate and glucuronide conjugates) and also undergoes oxidation by CYP3A4.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal (55-60% as metabolites, 25-30% as unchanged drug and conjugates), biliary/fecal (30-35% as metabolites).
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Norethindrone: 80-90% bound to SHBG and albumin; ethinyl estradiol: 97-98% bound to albumin.
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Norethindrone: 4.0 L/kg (distribution extensive into tissues); ethinyl estradiol: 4.5 L/kg (high tissue binding).
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: norethindrone 50-77% (first-pass metabolism); ethinyl estradiol 38-48% (first-pass metabolism).
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No adjustment required for mild to moderate renal impairment. Use with caution in severe renal impairment (GFR <30 m L/min) due to potential fluid retention.
No data available for fictional drug ALYACEN 777.
Contraindicated in acute hepatic disease or hepatocellular carcinoma. For mild hepatic impairment (Child-Pugh A), use with caution; no specific dose adjustment established. Avoid in moderate to severe (Child-Pugh B or C) due to impaired hormone clearance.
No data available for fictional drug ALYACEN 777.
Not indicated for use before menarche. For postmenarchal adolescents, dosing is same as adults: one tablet orally once daily.
No data available for fictional drug ALYACEN 777.
Not indicated for use after menopause. No specific geriatric dosing recommendations; consider risk of thrombotic events and comorbidities.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases the risk of serious cardiovascular adverse effects from combination oral contraceptives (COCs). This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Thrombotic and other vascular events (e.g., venous thromboembolism, myocardial infarction, stroke),Liver disease (e.g., hepatic adenomas, hepatocellular carcinoma),Elevated blood pressure,Carbohydrate and lipid metabolic effects,Gallbladder disease,Dermatologic conditions (e.g., chloasma, photosensitivity),Ocular effects (e.g., retinal thrombosis),Depression,Cervical cancer screening,Hereditary angioedema,Interference with laboratory tests
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Active liver disease (e.g., acute viral hepatitis, severe cirrhosis),Hypersensitivity to any component of the product,Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No specific food interactions are known for DASETTA 1/35. However, grapefruit juice may increase estrogen levels by inhibiting CYP3A4 metabolism; consider limiting grapefruit intake. St. John's Wort can reduce efficacy of oral contraceptives and should be avoided.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
Category X. First trimester: Risk of cardiovascular defects and neural tube defects; second and third trimesters: Risk of female genital tract anomalies (e.g., vaginal adenosis, clear cell adenocarcinoma) due to diethylstilbestrol component.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Contraindicated. Diethylstilbestrol is excreted in breast milk; M/P ratio unknown. Potential estrogenic effects in infants. Alternative contraception recommended.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
Dose adjustments not applicable due to contraindication in pregnancy. No pharmacokinetic studies available to guide dosing.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
DASETTA 1/35 is a monophasic combination oral contraceptive containing 1 mg norethindrone and 35 mcg ethinyl estradiol. It is used for contraception and may also regulate menstrual cycles. The pill-free interval is 7 days. Instruct patients to take one tablet daily at the same time. If a pill is missed, follow standard missed pill guidelines: if missed by <24 hours, take it immediately; if by >24 hours, take the missed pill and skip the placebo week. Breakthrough bleeding is common in the first few cycles; consider adjusting estrogen dose if persistent. Counsel about increased thromboembolic risk in smokers >35 years old.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one tablet at the same time every day for 21 days, then 7 placebo pills.,Start the pack on the first Sunday after menstruation begins or on the first day of menses.,If you miss a pill, take it as soon as remembered unless >24 hours late; then take two pills the next day.,Use backup contraception (e.g., condoms) if you miss more than one pill or if vomiting/diarrhea occurs within 4 hours of taking a pill.,Report signs of blood clots: sudden leg pain, shortness of breath, chest pain, or headache.,Do not smoke while taking this medication, especially if over 35 years old.,The pill does not protect against sexually transmitted infections.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DASETTA 1/35 vs ALYACEN 777, answered by our medical review team.
DASETTA 1/35 is a Oral Contraceptive that works by Combination of an estrogen (ethinyl estradiol) and a progestin (norethindrone). Suppresses gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, induces changes in cervical mucus (impenetrability to sperm) and endometrium (reduced likelihood of implantation).. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DASETTA 1/35 and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DASETTA 1/35 is: One tablet orally once daily, each containing 1 mg norethindrone acetate and 35 mcg ethinyl estradiol.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DASETTA 1/35 and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DASETTA 1/35 is classified as Category C. Category X. First trimester: Risk of cardiovascular defects and neural tube defects; second and third trimesters: Risk of female genital tract anomalies (e.g., vaginal adenosis, cl. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.